Willow keeps semaglutide billing simple but not cheap. No membership fee, a flat $299/mo for semaglutide, and the injection-or-oral-tablet choice are genuine positives. But semaglutide sits above low-cost peers, tirzepatide is dose-tiered and climbs to about $549/mo at higher doses, it is available in only about 33 states, it does not clearly name its compounding pharmacy, and review trust signals are mixed and limited.
Willow at a glance
- Category:
- Telehealth weight-loss (GLP-1)
- Medication:
- Compounded semaglutide & tirzepatide (not FDA-approved)
- Semaglutide:
- $299/mo flat (injection or oral tablet)
- Tirzepatide:
- Dose-tiered ~$299–$549/mo by dose
- Membership fee:
- None
- Dose pricing:
- Semaglutide flat; tirzepatide rises with dose
- States:
- ~33 states (early 2026; verify)
- Pharmacy:
- Not clearly named (verify)
- Reviews:
- Rating pending verification
- Clinical model:
- Telehealth prescribing; sema as injection or oral tablet
- Regulatory note:
- None identified as of June 2026; verify
Pros and cons
What we like
- No membership fee; all-in pricing incl. shipping + support
- Flat $299/mo for semaglutide
- Multiple formats (injection, oral, sublingual)
- Fast onboarding and delivery
Trade-offs to know
- Higher entry price ($299+) than low-cost peers
- Tirzepatide cost rises steeply by dose (to ~$549/mo)
- Available in only about 33 states
- Does not clearly name its compounding pharmacy
- Mixed and limited review trust signals
- Medication is compounded — not FDA-approved
Scorecard
Scored on the same five-criterion rubric we apply to every provider. Weights in parentheses.
Pricing: flat and predictable
Willow charges a flat $299/mo for compounded semaglutide (injection or oral tablet). Compounded tirzepatide is dose-tiered, running roughly $299 to $549/mo depending on the dose rather than a single flat price, so the tirzepatide bill climbs as your dose increases. There is no membership fee. The trade-off is that the entry price sits above the lowest-cost providers in our comparison, and higher tirzepatide doses get expensive, so if headline price is your priority you can find cheaper medication elsewhere. Verify current pricing on startwillow.com.
Pharmacy & sourcing
Willow does not clearly name its current compounding pharmacy in its published materials (verify). Because compounded drugs are not FDA-approved, an undisclosed pharmacy removes a key way for patients to verify sourcing and request a certificate of analysis. This weighs on Willow's score regardless of its pricing clarity.
Reviews & reputation
We have not verified Willow's third-party rating to a primary source, so we show its rating as pending verification rather than publish an unconfirmed number. Reviews sit on a smaller base and one review outlet described Willow as "flat pricing, bumpy on trust," which we read as mixed trust signals rather than a clear verdict either way; verify current listings, since a smaller review base can move quickly.
Regulatory context
We identified no regulatory actions or lawsuits involving Willow as of June 2026; verify current dockets and listings. We note this because regulatory posture is part of our rubric; the absence of identified issues is presented factually, not as an endorsement.
Who Willow is best for
Choose Willow if you want a flat $299/mo semaglutide with no membership and you like the option of an oral tablet, and you live in one of its ~33 states. Consider our #1 pick instead if you want a lower all-in price, tirzepatide that doesn't climb with dose, and a provider that names its pharmacy — see our MaxLife review.
Willow FAQ
How much does Willow really cost?
Willow charges $299/mo for compounded semaglutide (available as an injection or an oral tablet). Compounded tirzepatide is dose-tiered, running roughly $299 to $549/mo depending on the dose rather than a single flat price. There is no membership fee. Verify current pricing on startwillow.com before deciding.
Does Willow name its compounding pharmacy?
Not clearly. Willow does not clearly name its current compounding pharmacy in its published materials (verify). Because compounded drugs are not FDA-approved, an undisclosed pharmacy removes a key way to verify sourcing.
Is Willow FDA-approved?
Willow's compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Compounded semaglutide is not Ozempic® or Wegovy®; compounded tirzepatide is not Mounjaro® or Zepbound®.